First Time Loading...

Pfizer Inc
NYSE:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
NYSE:PFE
Watchlist
Price: 27.81 USD 0.4% Market Closed
Updated: May 6, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement
|
Revenue Breakdown

Revenue Breakdown

Breakdown by Geography
Pfizer Inc

Total Revenue: 58.5B USD
100%
United States: 27.1B USD
46.3%
Emerging Markets: 12B USD
20.5%
Developed Europe: 11.7B USD
19.9%
Developed Rest Of World: 7.8B USD
13.3%
Show More
Show Less

Breakdown by Segments
Pfizer Inc

Total Revenue: 58.5B USD
100%
Biopharma: 57.2B USD
97.8%
Comirnaty Direct Sales And Alliance Revenues: 11.2B USD
19.2%
Eliquis Alliance Revenues And Direct Sales: 6.7B USD
11.5%
Prevnar Family: 6.4B USD
11%
Ibrance: 4.8B USD
8.1%
Vyndaqel Family: 3.3B USD
5.7%
All Other Specialty Care: 2.2B USD
3.8%
All Other Primary Care: 1.8B USD
3%
Xeljanz: 1.7B USD
2.9%
Business Innovation Segment: 1.3B USD
2.2%
Paxlovid: 1.3B USD
2.2%
Pfizer Centreone: 1.3B USD
2.2%
Xtandi Alliance Revenues: 1.2B USD
2%
All Other Anti-Infectives: 1.1B USD
1.9%
Inlyta: 1B USD
1.8%
Nurtec Odt/Vydura: 928m USD
1.6%
Abrysvo: 890m USD
1.5%
Enbrel (Outside The United States And Canada): 830m USD
1.4%
Sulperazon: 757m USD
1.3%
Bosulif: 645m USD
1.1%
Ig Portfolio: 584m USD
1%
Genotropin: 539m USD
0.9%
Lorbrena: 539m USD
0.9%
Zavicefta: 511m USD
0.9%
Inflectra: 490m USD
0.8%
All Other Oncology: 433m USD
0.7%
Benefix: 424m USD
0.7%
Zirabev: 424m USD
0.7%
Zithromax: 406m USD
0.7%
Premarin Family: 397m USD
0.7%
Ruxience: 390m USD
0.7%
Xalkori: 374m USD
0.6%
Retacrit: 340m USD
0.6%
Medrol: 339m USD
0.6%
Bmp2: 338m USD
0.6%
Oxbryta: 328m USD
0.6%
Aromasin: 301m USD
0.5%
Fsme-Immun/Ticovac: 268m USD
0.5%
Somavert: 267m USD
0.5%
Fragmin: 238m USD
0.4%
Besponsa: 236m USD
0.4%
Refacto Af/Xyntha: 230m USD
0.4%
Braftovi: 213m USD
0.4%
Cresemba: 195m USD
0.3%
Bavencio Alliance Revenues: 190m USD
0.3%
Vfend: 187m USD
0.3%
Sutent: 180m USD
0.3%
Nimenrix: 179m USD
0.3%
Mektovi: 174m USD
0.3%
Bicillin: 158m USD
0.3%
Cibinqo: 128m USD
0.2%
Trumenba: 126m USD
0.2%
Trazimera: 91m USD
0.2%
Padcev: 52m USD
0.1%
Adcetris: 46m USD
0.1%
Pfizer Ignite: 44m USD
0.1%
Tukysa: 17m USD
0%
Tivdak: 4m USD
0%
Show More
Show Less

See Also

Summary
PFE intrinsic value, competitors valuation, and company profile.
DCF Valuation
PFE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PFE stock valuation using valuation multiples.
Wall Street Estimates
PFE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PFE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 134,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.